Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

Distribution of EGFR R521K Polymorphism in Different Iranian Ethnic Groups

Asal Shahrokhshahi 1 and Massoud Houshmand 2 , *
Authors Information
1 Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, IR Iran
2 Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: 18 (4); e6438
  • Published Online: April 27, 2016
  • Article Type: Short Communication
  • Received: September 29, 2015
  • Accepted: December 12, 2015
  • DOI: 10.17795/zjrms-6438

To Cite: Shahrokhshahi A, Houshmand M. Distribution of EGFR R521K Polymorphism in Different Iranian Ethnic Groups, Zahedan J Res Med Sci. Online ahead of Print ; 18(4):e6438. doi: 10.17795/zjrms-6438.

Copyright © 2016, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis. 2008; 23(7): 683-8[DOI][PubMed]
  • 2. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010; 13(2): 143-6[PubMed]
  • 3. Satia-Abouta J, Galanko JA, Potter JD, Ammerman A, Martin CF, Sandler RS, et al. Associations of total energy and macronutrients with colon cancer risk in African Americans and Whites: results from the North Carolina colon cancer study. Am J Epidemiol. 2003; 158(10): 951-62[PubMed]
  • 4. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009; 22(4): 191-7[DOI][PubMed]
  • 5. Davies RL, Grosse VA, Kucherlapati R, Bothwell M. Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. Proc Natl Acad Sci U S A. 1980; 77(7): 4188-92[PubMed]
  • 6. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PJ. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002; 29(1 Suppl 4): 3-14[PubMed]
  • 7. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7): 505-16[DOI][PubMed]
  • 8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11): 1160-74[DOI][PubMed]
  • 9. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983; 1(5): 511-29[PubMed]
  • 10. Moriai T, Kobrin MS, Korc M. Cloning of a variant epidermal growth factor receptor. Biochem Biophys Res Commun. 1993; 191(3): 1034-9[DOI][PubMed]
  • 11. Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A. 1994; 91(21): 10217-21[PubMed]
  • 12. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008; 14(23): 7884-95[DOI][PubMed]
  • 13. Wang WS, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res. 2007; 13(12): 3597-604[DOI][PubMed]
  • 14. Hsieh YY, Tzeng CH, Chen MH, Chen PM, Wang WS. Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. Cancer Sci. 2012; 103(4): 791-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments